Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$2,058.61
+959.18% vs spot
Strong Buy
Spot price
$194.36
Mkt cap $12.48B
subtle cardAnalyst PT consensus
$168.67
-13.22% vs spot
subtle cardMethods covered
14 / 16
14 in blend
subtle cardFootball field
DVA · fair-value range by method
Method comparison
DVA · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $5,476.21 | $2,480.84 – $16,119.04 | +2717.56% | 23.7% | WACC 3.2%, g₀=25.0%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $704.38 | $531.80 – $960.60 | +262.41% | 17.8% | kₑ 8.2%, g₀=25.0%, gₗ=2.0% | high |
| Residual income | income | $66.88 | $58.86 – $74.91 | -65.59% | 11.8% | BV 22.23, ROE 64.5% → kₑ | high |
| EVA / MVA | income | $5,647.29 | $4,969.61 – $6,324.96 | +2805.58% | 8.3% | IC 15.5B, WACC 3.2% | high |
| P/E · sector | multiple | $209.22 | $184.11 – $234.33 | +7.65% | 14.2% | EPS 9.51 × peer P/E 22.0 | med |
| P/S · sector | multiple | $1,047.03 | $889.98 – $1,204.09 | +438.71% | 3.6% | Rev/sh 261.76 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $486.16 | $427.82 – $544.50 | +150.13% | 11.8% | EBITDA × peer 15.0× − ND 14.3B | high |
| EV / EBIT | multiple | $420.15 | $357.13 – $483.18 | +116.17% | 2.4% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $615.76 | $523.40 – $708.13 | +216.82% | 2.4% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $380.40 | $323.34 – $437.46 | +95.72% | 1.2% | PEG=1, fwd EPS g 54.6% | med |
| Earnings power | intrinsic | $657.72 | $578.80 – $736.65 | +238.41% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $455.03 | $386.78 – $523.28 | +134.12% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $237.75 | $202.09 – $273.41 | +22.32% | 0.6% | PE = g (25.0) | low |
| Book NAV | asset | $22.23 | $21.11 – $23.34 | -88.56% | 1.2% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | — | — | — | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -20.0% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.84)β | × 0.84 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 8.19% |
| Pre-tax cost of debtkd | 3.65% |
| Effective tax ratet | 21.8% |
| After-tax cost of debt | 2.86% |
| Equity weight$1.2B | 7.1% |
| Debt weight$15.0B | 92.9% |
| WACC | 3.24% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 3.28% |
| Analyst forward EPS growthFMP | 54.59% |
| Historical 5y revenue CAGRFY | 4.10% |
| Historical 5y EPS CAGRFY | 1.67% |
| Sustainable g (ROE × retention)Δ | 64.47% |
| Blended near-term growth (g₀) | 25.00% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2022-12-30)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $168.67
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.